Biotech & Pharma

SonoThera Raises $125M to Develop Ultrasound-Mediated Genetic Medicines

33 sec read5 views0 listens

SonoThera has secured $125 million in Series B financing to advance its ultrasound-mediated genetic medicine platform toward clinical trials. This development is significant for the biotech sector because the proprietary RIPPLE and PORE technologies address traditional gene therapy barriers like payload size and immune responses. By enabling precise and redosable treatments, the company is positioning itself to tackle previously inaccessible diseases such as Duchenne muscular dystrophy. Success in upcoming 2027 trials could fundamentally change the delivery landscape for DNA and RNA therapeutics.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

STAT+: Pharmalittle: We're reading about a discontinued cancer drug, a Novo security breach, and more

The nonprofit Blood Cancer United has acquired the remaining supplies and investigational rights for the discontinued drug Luvelta to continue providing it to children with rare blood cancers. This unusual move highlights a critical shift in the phar...

Ali Nemati

Biotech & Pharma2 days ago30 sec read

In Silico Devices May Improve Drug Manufacturability

In silico tools, particularly AI-driven predictive models, can significantly improve drug manufacturability by identifying potential issues early in the development process. BigHat Biosciences demonstrates that by augmenting physical experiments with...

Ali Nemati

Biotech & Pharma2 days ago30 sec read

10x Genomics Acquires Proteintech Genomics, Expanding Proteomics Capablities

10x Genomics has acquired Proteintech Genomics to integrate high-plex protein detection capabilities into its existing single-cell and spatial biology platforms. This acquisition matters to biotech professionals as it enables the harmonization of RNA...

Ali Nemati

Health & Medicine2 days ago27 sec read

STAT+: Pharmalittle: We're reading about U.S. pressure on European drug prices, longer shortages, and more

The number of prescription drug shortages in the U.S. has decreased overall but the duration of existing shortages has significantly increased, now averaging over five years. Concurrently, European countries are facing divergent approaches to drug pr...

Ali Nemati

Biotech & Pharma3 days ago26 sec read

First-in-Human Trial Reports Promising Dual Lassa-Rabies Vaccine Data

A dual vaccine targeting Lassa fever and rabies has proven safe and immunogenic in first-in-human clinical trials. This development is significant for global health professionals because the vaccine utilizes a freeze-dryable platform that bypasses tr...

Ali Nemati

SonoThera Raises $125M to Develop Ultrasound-Mediated Genetic Medicines

Related Articles

STAT+: Pharmalittle: We're reading about a discontinued cancer drug, a Novo security breach, and more

In Silico Devices May Improve Drug Manufacturability

10x Genomics Acquires Proteintech Genomics, Expanding Proteomics Capablities

STAT+: Pharmalittle: We're reading about U.S. pressure on European drug prices, longer shortages, and more

First-in-Human Trial Reports Promising Dual Lassa-Rabies Vaccine Data